Efficacy and Safety of Omalizumab in Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial

被引:0
|
作者
Casale, Thomas [1 ]
Maurer, Marcus [2 ]
Hsieh, Hsin-Ju [3 ]
Canvin, Janice [4 ]
Saini, Sarbjit S. [5 ]
Grattan, Clive [6 ]
Gimenez-Arnau, Ana [7 ]
Kaplan, Allen P. [8 ]
Rosen, Karin [3 ]
机构
[1] Creighton Univ, Med Ctr, Omaha, NE USA
[2] Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Novartis Pharmaceut UK Ltd, Horsham, W Sussex, England
[5] Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA
[6] Norfolk & Norwich Univ Hosp, Dept Dermatol, Norwich, Norfolk, England
[7] Univ Autonoma Barcelona, Hosp Mar, Dept Dermatol, E-08193 Barcelona, Spain
[8] Med Univ S Carolina, Charleston, SC 29425 USA
关键词
D O I
10.1016/j.jaci.2012.12.1546
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
引用
收藏
页码:AB327 / AB327
页数:1
相关论文
共 50 条